# Timing of Empagliflozin in Primary PCI: Pre-Reperfusion Versus Post-Reperfusion Versus Placebo in South Asian STEMI Patients

> **NCT07749014** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Rehman Medical Institute - RMI** · enrollment: 480 (estimated)

## Conditions studied

- ST-elevation Myocardial Infarction (STEMI)
- Acute Myocardial Infarction (AMI)
- Coronary Artery Disease

## Interventions

- **DRUG:** empagliflozin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07749014
- **Lead sponsor:** Rehman Medical Institute - RMI
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09-01
- **Primary completion:** 2027-09-30
- **Final completion:** 2027-09-30
- **Target enrollment:** 480 (ESTIMATED)
- **Last updated:** 2026-08-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07749014

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07749014, "Timing of Empagliflozin in Primary PCI: Pre-Reperfusion Versus Post-Reperfusion Versus Placebo in South Asian STEMI Patients". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07749014. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*